Call us now0755-8668-0658 E-mailinfo@immuclin.com

Company Introduction

Shenzhen Immuclin Biomed, Inc. is a biotechnology firm that focuses on research and development of ACTL technology and its products for cancer treatment.
ACTL is a type of cancer immunotherapy with cytotoxic T lymphocytes (CTL) activated by adeno-associated virus (AAV) with antigen gene transferred dendritic cells (DC). The CTL can identify and eliminate the tumor cells after being infused back to patient’s body. The treatment efficacy has been greatly improved with Immuclin’s patented technologies, compared to the conventional immunotherapies.
The technology has been advanced to the fifth generation. Over 30 types of products are used in the ACTL treatment. The treatment is available in over 50 leading hospitals in China and Thailand.
A series of quality control systems have been developed to ensure the safety of the ACTL treatment. These systems have been awarded with ISO9001, ISO14001 and OHSAS18001 certifications. In 2015, Immuclin has been recognized as a National Hi-Tech Enterprise by the Chinese Ministry of Science and Technology.

19
19 International and Chinese Patents
50
50 Patents in 5 Years
25
Standardized Production of 25 Products
50
Collaboration with Over 50 Leading Hospitals in China
5000
Nearly 5000 Patients Treated

Our Culture

  • Mission

    Spread love and hope;


    Continue to write the legend of life for cancer patients


  • Vision

    Become an industry standard maker,


    Become a world-class biomedical company


  • Philosophy

    Profession-oriented, effective results

  • Human Resource

    People make the best use of their talents

  • Service

    Patient satisfaction is our only criterion

  • Management

    Integrity, teamwork, creativity

  • Product idea


    Effect is the only criterion for testing product concept

  • Corporate style


    Rigorous and realistic

Milestones

  • 2020s
    In September 2020, the State Intellectual Property Office granted Shenzhen Yishi Kangning Biotechnology Co., Ltd. an invention patent for "A Recombinant Adeno-Associated Virus Vector Carrying Tumor-Testis Antigen 10 Gene and Its Application Value". This patent is Yishi Kangning. Obtained the 14th Chinese invention patent.
  • 2020s
    On April 17, the company held a knowledge training about ACTL.
  • 2020s
    Resume epidemic prevention and work in accordance with government requirements
  • 2020s

    The annual meeting of "2019 Year-end Summary and 2020 New Year" will be held on January 8.

    January 9-11, Guangdong Meizhou + Fujian Yongding three-day tour

  • 2019s
    In September, the company moved to the 7th floor of Building A, Tongfang Information Port, No. 11, Langshan Road, North District, Nanshan District, Shenzhen.
select
  • 2018s
     On January 24, the company organized the "Iscoming 2017 Annual Commendation and 2018 New Year's Eve."
    From January 25th to 26th, the company held the 2018 ISKCON New Year Party and a 2-day tour of OCT East.
  • 2018s

    On March 15th, the leaders of the Doctorate Education of Sun Yat-sen University visited our company.
    On March 28th, Longlink Life Technology Co., Ltd. visited our company.

  • 2018s

    On April 1, guests from Jiangsu, Hainan, Xinjiang, Henan and other places visited our company.

    On April 20th, Deputy Director Zhu of the Oncology Department of Jiangsu Provincial People's Hospital visited our company for a visit and exchange.

    After the company's research and decision, Zhang Wenli was selected as the April "Employee Star" and Shi Pengyan as the April "Manager Star".

  • 2018s

    On May 15, the leaders of Guangxi Nanning High-tech Industrial Development Zone Management Committee visited our company for a visit and exchange.

    On May 18, the company held a birthday party for employees from January to May, and sent sincere wishes.

    On May 22, the company purchased Shenzhen's 2018-2019 supplementary medical insurance for major diseases for Shenzhen social security employees.

    On May 24, the company organized relevant colleagues to study ACTL knowledge at CMD in Guangzhou.

    After the company's research and decision, Wang Yuan was selected as the "Employee Star" in May and Xu Yanwei as the "Manager Star" in May.

  • 2018s

    On June 4, the leaders of the Chongqing Municipal Committee of the Chinese People's Political Consultative Conference visited our company for a visit and exchange.

    On June 8, Mr. Wu from Jiaquan Firm visited our company to hold a kick-off meeting for the implementation of intellectual property standards.

    After the company's research and decision, Xie Xiaoyun was selected as the "Employee Star" in June and Wang Jing as the "Manager Star" in June.

  • 2018s

    On July 23 and 25, the leaders of Nanshan Water Environment Bureau visited the company. Shi Pengyan of the project department and Gao Hongji, head of the laboratory, received them together and communicated with them on laboratory environmental assessment related issues.

    On July 24, the company's R&D laboratory EIA application was approved by the Nanshan District Water Environment Bureau!

    After the company's research and decision, Wang Hongliang was selected as the "Employee Star" in July and Jiang Xiaoqing as the "Manager Star" in July.

  • 2017s

    From January 9th to January 23rd, the technical staff training of Zhejiang Provincial People's Hospital was successfully completed, and excellent results were obtained.

  • 2017s

    On February 14th, Li Zhong, a regional technician in Beijing, joined the company.

    On February 15th, Zhejiang Prostate Cancer Multi-center Clinical Research Experiment Project was launched in Zhejiang Provincial People's Hospital.

    On February 17, Dunyao, a technician in Jiangsu, joined the company.

    On February 25, Zheng Heming, Dean of Henan Zhengzhou 153 Hospital visited our company.

    After the company's research and decision, the February employee star "Zhang Wenli" and the manager star "Li Xiaolan" were selected.

  • 2017s

    On March 1, our company organized the "Iskoning 2016 Work Summary and 2017 Work Plan Meeting".

    From March 2nd to March 3rd, the company held its 5th anniversary celebration. On the evening of the 2nd, the "Don't Forget Your Original Aspiration, Go Forward Together-Yishi Kangning 5th Anniversary Party" held at Nankunshan Grand View Garden Hotel was a complete success.

    On March 6, Liao Chunhua, a technician from Shenzhen Experimental Center, joined the company.

    On March 11th, Professor Li Jicheng from the School of Medicine of Guangzhou University of Technology visited our company for a visit and exchange.

    On March 14, "Ye Qiuyi" was appointed as the head of the administrative department and "Li Chan" as the manager of the production department.

    On March 17, Su Zhituan, Chairman of the Board of Directors of Taidong Group, visited our company for a visit and exchange.

    On March 18th, Dean Jin Jie of Beijing Peking University Hospital and his entourage visited our company.

    On March 21st, the leaders of Shandong Brother Libang Company visited our company for exchange.

    The company decided to select “Li Aiqing” as the employee star in March and “Shi Pengyan” as the manager star in March.

  • 2017s

    On April 1st, Xu Jingang, Human Resources Department, joined the company.

    On April 1, Zhang Mingming was promoted to the director of the quality management department, Wang Hongliang was promoted to the director of the technical support department, Zhang Wenli was promoted to the director of the technical support department, Li Aiqing was promoted to the director of the experimental center, and Ling Min was appointed as the director of the finance department.

    April 5th, Liu Feihu, a technician in the production department, joined the company.

    April 17 Technician Nie Beina from Shenzhen Experimental Center joined the company.

    On April 25th, Mr. Yao Xingquan, Chairman of Star Platinum International (Hong Kong) Holdings Co., Ltd. visited our company for a visit.

    April 26 Niu Zuowen appointed the manager of the administration department.

    On April 28, Shenzhen Yishi Kangning Biotechnology Co., Ltd. and Singapore's REGENE GROUP (REGENE GROUP) ACTL technology project cooperation agreement was successfully held to establish an anti-cancer biological treatment center in Singapore.

    The company decided to select “Wang Hongliang” as employee star in April and “Qin Baoxi” as manager star in April.

  • 2017s

    58号至24号,第三批培训班:徐州二院,南通大学附属医院,CMD医院的5名技术人员培训圆满结束,并且取的优良成绩。

    515日,采购&库管部助理刘清入职。

    529日,公司为深圳社保员工统一购买了深圳市2017-2018年度重特大疾病补充医疗保险。

    经公司研究决定评选5月 员工之星 “陈燕”,5月 经理之星“陈荣华”。

  • 2017s


    In June, Shandong Yishilibang Biotechnology Co., Ltd. was formally established.

    On June 6, Liu Xiaoyu, a nurse in the Technical Support Department, entered the job.

    On June 19th, Wang Jing, the QA supervisor of the Quality Management Department, joined the company.

    On June 19th, Yu Lei, the market area manager of the Jiangsu team joined the company.

    On June 23, the company and its Malaysian partners reached a preliminary cooperation agreement on the cooperation between the two parties to carry out the research, development, promotion and application of ACTL treatment technology in the local area.

    On June 27, the company conducted fire safety training.

    According to the company's research and decision, Song Ge was selected as the "Employee Star" in June and Tang Huijuan as the "Manager Star" in June.


  • 2017s

    On July 4, Li Fei, the regional manager of the marketing department, joined the company.

    On July 17, Wu Juan, the scientific research secretary of the Jiangsu team, joined the company.

    On July 28, the company held a birthday party for employees from May to July, sending the most sincere wishes.

    After the company's research and decision, Huang Jialiang was selected as the "Employee Star" in July and Zhang Hui as the "Manager Star" in July.





  • 2016s

    In January, the marketing department successively received leaders and experts from Tianjin Jixing Hospital, Chairman Li Tong, Honghe Prefecture People's Hospital, Teacher Li Linhe, Zhenxing Xiangya Health Management Co., Ltd. and other leaders and experts to visit and guide;

    In January, Dai Zhong, the manager of the marketing department, represented our company in the defense of the cell therapy project of Anhui Chest Hospital. Our ACTL technology took the lead among many competitors and won the bid first;

    On January 6, the "Notice on Late Marriage Leave" was released;

    On January 7, the project department received the national high-tech enterprise certification, and the company successfully reached a new level of qualification;

    On January 20, the "2015 Annual Summary and Commendation" was organized. Professor Liu summarized the work in 2015 and made work deployment for 2016; the heads of various departments also summarized the work in 2015 and made plans for the work in 2016. Company leaders awarded honor certificates and bonuses to outstanding employees Gao Hongji, Zhang Mingming, Xu Yanwei, Song Jing, Huang Jialiang and the experimental center that won the outstanding team in 2015; awarded Shi Pengyan the annual outstanding contribution award honorary certificate; Gao Hongji and other 17 people awarded the annual Honorary certificate of contribution award. On the 21st and 22nd, the company organized a two-day tour in the province and the 2016 welcome party.

    On January 21, Qujing First People's Hospital officially launched the first case of ACTL technical treatment;

    On January 26, the “Spring City Evening News”, the newspaper with the largest circulation in Yunnan, reported that the Central Laboratory of the Second People’s Hospital of Yunnan Province promoted biological cell immunotherapy and scientific research, and achieved DC-T cell immunotherapy for hepatitis B and ACTL cells for tumors. Targeted therapy;

    At the end of January, the company launched the 2015 annual performance appraisal year-end general evaluation and managerial satisfaction survey.

  • 2016s

    On February 1, Hefei Tumor Hospital of Anhui Chinese Academy of Sciences officially launched the application of ACTL technology, and both patients achieved significant results after reinfusion;

    On February 15, Li Changrong, deputy general manager, joined;

    On February 15, Tang Huijuan, manager of the finance department, joined the company;

    On February 23, Lei Shaohua, Regional Manager of Marketing Operations Department, joined;

    In February, signed a market cooperation agreement with Guangzhou Zisheng Biotechnology;

    After the recommendation of various departments and the company's research and selection decision, the "employee star" of January and February was selected as: Wang Hongliang of Shenzhen Experimental Center; and the "manager star" of January and February was: Zhang Hui of Shenzhen Experimental Center.

  • 2016s

    On March 4, Tang Chunhua, Administrative Assistant of the Administration Department, joined the company;

    On March 10th, leaders of major hospitals and department heads of the Maternal and Child Health Hospital of Shenzhen Dapeng New District visited our company.

    On March 13, the Jiangsu multi-center non-small cell lung cancer trial kick-off meeting was held in Nanjing, marking the “ACTL Targeted Anti-tumor Cell Immunotherapy Technology Multi-center Multi-center Research” led by the Jiangsu Health and Family Planning Commission and the First Affiliated Hospital of Nanjing Medical University. The scientific research project of clinical trial research was officially launched.

    On March 15, the deputy director of the General Office of the Shenzhen Municipal Party Committee and the director of the High-tech Division of the Science and Technology Commission visited the company. The leaders of the municipal party committee carefully listened to the company’s leader Professor Liu’s corporate development needs, affirmed the company’s development and said that they would actively help the company to solve the problem difficult.

    On March 15th, Dai Rui, Regional Manager of Marketing Operations Department, joined the company;

    On March 16, Luo Xu, Sales Supervisor of Marketing Operations Department, joined;

    On March 16, the Human Resources Department organized two promotions for employees: Zhong Jianhui was promoted to the head of the quality management department, and Sun Peishu was promoted to the head of the project department, effective from April 1, 2016;

    On March 23, the pilot zone's hydropower management system was promulgated to strengthen and standardize the pilot zone's management.

    On March 25, the Human Resources Department issued the "Iskoning 2016 Employee Training Plan" based on the 2016 training needs of various departments and the company's actual situation;

    On March 29th, the Human Resources Department organized the heads of various departments to learn "How to prepare job descriptions and how to extract performance indicators", and issued the company job description template and work schedule;

    Congratulations to the company for successfully passing the AAA credit rating of China International Electronic Commerce Center with the credit code: BCP08924329.

    After the recommendation of various departments and the company's research and selection decision, the "employee star" in March was selected as: Chen Zheyu from the technical support department; and the "manager star" in March was: Lai Weijie from the administration department.

  • 2016s

    On April 6, Shenzhen Science and Technology Innovation Committee announced the first batch of technology innovation coupon projects in 2016, and the company was among them!

    On April 6, the Human Resources Department organized and carried out the "Preparation of Job Description and Performance Index Extraction Discussion and Study Meeting";

    On April 8, the leaders of the Investment Promotion Bureau of Binjiang Development Zone, Hangzhou, Zhejiang Province visited our company in person;

    On April 11, the Human Resources Department issued the newly revised "Market Operations Department and International Department Sales Incentive Program", effective from April 1, 2016;

    On April 20th, Xue Xiangzhen, director of marketing operations in North China, joined;

    On April 20th, Ye Qiuyi, administrative assistant of the Administration Department, joined;

    On April 23, leaders and experts from Zhejiang Provincial People's Hospital visited and guided;

    From April 25th, Tang Chunhua acted as a human resources assistant and at the same time acted as a secretary for Professor Liu;

    On April 25th, leaders of Yuedong Hospital of the Third Affiliated Hospital of Sun Yat-sen University visited our company for guidance;

    On April 26th, Yan Wu from the Technical Support Department conducted a scientific conference at the Beijing Armed Police General Hospital to explain ACTL technology and applications, which was well received by the participating doctors and experts.

    On April 26, the Human Resources Department organized a study meeting on the newly revised "Employee Handbook" and related human resources systems;

    On April 27th, Tan Baoxi, director of network operations, joined the company.

    On April 29, the company's internal publicity wall hanging and conference hardware facilities were upgraded, and the company's external reception capabilities were further improved.

    On April 30th, we received Professor Ahmad, the former director of the Department of Doctors of the Ministry of Health of Indonesia, and several chairmen and experts of local medical groups.

    The Human Resources Department organized the selection of April "Employee Star" and April "Manager Star".

  • 2016s

    May 4, Yang Qin, head of customer service department, joined the company.

    On May 6th, the ACTL and TKI multi-center research project signing meeting for the treatment of lung cancer was successfully held in Nanjing Zhongshan Hotel.

    On May 16th, the conference room project renovation was completed, and the OTV video conference system was officially launched. The company's external publicity and training hardware facilities were further upgraded.

    On May 16, Xu Yanwei was appointed as the deputy director of the marketing department, and the regional manager of the second district of South China, and Dong Wenjuan, the director of the production department, also served as the production manager.

    May 17 Released "Iscoming Organizational Structure and Departmental Structure Chart 201601".

    On May 18, the project department, financial department, and production department related personnel in Shenzhen Software Park applied to the company to apply for the 2014 Municipal Science and Technology Innovation Commission project defense successfully completed.

    On May 19, we received visits from Wu Shuhuang, director of the Science and Technology Commission of Chongqing Dadukou District Government, Ding Zhu, deputy director, and leaders of the Science and Technology Innovation Commission.

    On May 24, Li Jianmeng trained "Problems and Thoughts on PPT of the Academy/Class Meeting" for the Marketing Department.

    On May 31, Tao Yi trained the "ACTL Load Antigen and Clinical Application" for the marketing department.

    The Human Resources Department organized the selection of May "Employee Star": Ni Chunmei "Manager Star": Tang Huijuan


  • 2016s

    June 7 Xu Yanwei trained the "Non-Small Cell Lung Cancer Clinical Promotion Plan" for the marketing department

    On June 14th, Zhang Mingming trained "A Brief Talk on ACTL Technical Quality Control Standard" for the Marketing Department

    On June 14th, the Ministry of Human Resources issued a new version of the "Kexing Science Park Parking Fee Subsidy Management Measures V3".

    On June 17th, the Ministry of Administration promulgated the "Administrative Measures for Delivery and Delivery of Express Delivery" to regulate and control company express delivery.

    On June 20th, the Human Resources Department organized a study meeting to convey the company’s spirit of instructions on performance appraisal.

    On June 20, the Ministry of Administration promulgated the "Enterprise Energy Management System", which strengthened the company's energy management, reduced energy consumption, eliminated waste, and improved energy utilization.

    June 21 Yan Wu trained "ACTL Related Immunology Knowledge Introduction" for the marketing department

    On June 23, the Human Resources Department issued a new version of the "Iskoning Employee Performance Appraisal Measures (2016)" and the performance appraisal content of each department.

    June 26 Dong Wenjuan trained the "Efficacy Evaluation of Tumor Treatment" for the Marketing Department

    On June 27th, the Human Resources Department issued the monthly work appraisal amendments of the Market Operations Department.

    On June 27, the project department completed the application for the Shenzhen Expert Database and passed the review. Professor Liu successfully entered the Shenzhen Science and Technology Innovation Committee Expert Database.

    On June 30, the Ministry of Administration promulgated the "Regulations on the Management of the Use of Fixed Telephones", which strengthened the management of the company's office telephones, saved expenses and reduced waste.

    June 30 The Administration Department organized "Business Etiquette Training" to enhance the external personal image and corporate image of employees.

    The Human Resources Department organized and selected Cai Haisong, the "Employee Star" in June, and Xu Yanwei, the "Manager Star" in June.


  • 2016s


    On July 5, the Administration Department promulgated the "Company Computer Management System" to standardize the computer and network management of company employees.

    On July 6, organize all employees to participate in emergency knowledge and skills training, learn CPR on-site emergency rescue knowledge and workforce sub-health occupational disease prevention and improvement, and enhance employees' comprehensive health knowledge.

    On July 7, the Administration Department promulgated the "Company Vehicle Management System" to strengthen the company's vehicle management, ensure driving safety, and reduce expenditures.

    On July 8, the Ministry of Administration promulgated the latest version of the "Provisions for the Administration of Official Travel in the Province V4.4", clarifying the implementation of the company's employees' official travel policies and guarantee policies in the province.

    On July 14, organized part of the company's personnel to participate in the "Chemical Laboratory Safety Management" training to improve the safety management capabilities of laboratory personnel.

    The company decided to select Li Chan as the “Employee Star” in July and Dong Wenjuan as the “Manager Star” in July.


  • 2016s


    On August 3, the original "Network Operations Department" was adjusted to the "Planning Department", and Tan Baoxi was appointed as the manager of the Planning Department.

    On August 4, Professor Liu attended the "Seventh Northern Regional Lymphoma Symposium" meeting in Beijing with a complete success.

    On August 31, Li Xiaolan was appointed as the human and administrative director, Yan Wu as the deputy manager of the technical support department, Li Chan as the deputy manager of the production department, Tang Chunhua as the secretary of Professor Liu, and Ye Qiuyi as the administrative acting supervisor.

    On August 31, due to his excellent work, Wang Hongliang was transferred to the technical support department, and Huang Jialiang was promoted to senior supervisor.


  • 2016s


    On September 1, the Shenzhen Science and Technology Innovation Award Conference and the Sixth Congress of the Shenzhen Municipal Committee of the Chinese People's Political Consultative Conference were held in Wuzhou Hotel. The conference was hosted by Mayor Xu Qin and Secretary Ma Xingrui delivered an important speech. Yishi Corning won the "Shenzhen Science and Technology Progress Award".

    On September 19, Fu Yaocai, a technician in the experimental center, joined the company.

    On September 22, Chen Yan, secretary of scientific research and marketing in Jiangsu, joined the company.

    On September 22-24, the 2016 Shenzhen International BT Summit and Biological Industry Exhibition was held in the Convention and Exhibition Center. More than 200 well-known international biological companies participated in this exhibition, focusing on releasing the latest scientific and technological achievements, showing cutting-edge technology and the future of the industry. Ishikoning was invited to participate in the exhibition as the representative company of Shenzhen Biological Incubator.

    On September 26, Song Ge, a research assistant in Jiangsu Province, joined the company.

    The multi-center clinical research in Jiangsu Province is progressing smoothly. On September 28, the company signed technical service contracts with Nanjing Congyi Pharmaceutical Company and Nanjing Medical University.

    The company decided to select Ye Qiuyi as the “Employee Star” in September and Zhang Hui as the “Manager Star” in September.


  • 2016s

    October 1st, Sun Pan, a cell culture technician in Jiangsu, joined the company.

    The company decided to select Li Aiqing as "Employee Star" in October and Tang Huijuan as "Manager Star" in October.

  • 2016s


    On November 14, the company decided to appoint Mr. Hang Ren as the deputy manager of the marketing department.

    On November 15, ACTL technology was reviewed and approved by the Hainan Health and Family Planning Commission.

    On November 18th, ACTL officially launched the groundbreaking ceremony for its technical center base in Hainan.

    On November 22, the Shenzhen Municipal Science and Technology Commission announced the results of the seventh batch of acceptance projects, and the company's technology development project approved in 2014 passed smoothly.

    According to the company's research, it was decided to select Wang Yuan as the "Employee Star" in November and Li Xiaolan as the "Manager Star" in November.


  • 2016s


    On December 5th, Finance Department Accountant Ling Min joined

    On December 16, in order to protect the health of employees, a physical examination was organized for all employees

    The 2016 Nanshan District Talent Supplementary Rent Project that the company applied for in November was successfully approved in December.

    From December 6th to December 22nd, the second batch of Jiangsu multi-center clinical trial training was successfully concluded, and the trainees achieved excellent results.

    According to the company’s research and decision, the “employee star “Sun Pan (Jiangsu team)” and the manager’s star “Gao Hongji” will be selected in December.


  • 2015s

    On January 4, Chen Zheyu, a technical support intern of the Technical Support Department, joined;

    On January 6, the Academic Department held the "Biotherapy Information Exchange Conference" and the company's "Biotherapy Bulletin" first issue promotion. Manager Tao Yi shared domestic and foreign biotherapy information with everyone, and the response was enthusiastic;

    On January 8, the Shenzhen innovative small, medium and micro enterprise filed by the company successfully obtained the certificate, and the company will be included in the key cultivation echelon of Shenzhen small, medium and micro enterprises;

    On January 12, after the company's research decision, Cai Haisong was appointed as the director of the experimental center;

    On January 15, the leaders of the Biology and Life Technology Division of the Shenzhen Municipal Science and Technology Innovation Committee came to the company for visit and guidance. The company is one of the three research companies in the cellular immunotherapy industry;

    On January 17, Manager Lu Jing conducted wonderful technical training for all regional managers;

    On January 18, the company organized the "2014 Work Summary Meeting" and a dinner for all employees;

    On January 19th, according to the invitation of the high-tech biological incubator, the project department represented the company to participate in the incubator company's New Year celebration. The leaders at the meeting included the director of the Shenzhen Science and Technology Commission, the director of the Municipal High-tech Office, and the person in charge of the incubator. The company spoke as a representative of the new enterprise and more than 30 enterprises participated in the meeting;

    On January 19, Lu Qiqian, a technical support intern of the Technical Support Department, joined;

    On January 19-31, the company organized the annual meeting of all employees in Thailand, "Bangkok Phuket 6-Day Luxury Tour". The first group of captains Zhang Hui and Ni Chunmei led the team for their outstanding performance, and they commended them;

    On January 20, the Shenzhen Life Science and Biotechnology Association held its first council meeting. The leaders at the meeting included the municipal science and technology innovation committee and the main leaders of the association. The company is the only governing unit in the cellular immunotherapy industry, and Professor Liu attended the meeting;

    In January, the company researched and decided to select Shenzhen Experimental Center Wang Yuan as the "Employee Star" of this month, and Gao Xue from the Finance Department as this month's "Manager Star" for encouragement.

  • 2015s

    On February 3, the Shenzhen Science and Technology Innovation Commission announced the results of the ninth batch of acceptance projects. The results of the entrepreneurial funding projects that the company applied for in 2012 and applied for acceptance in 2014 were "passed";

    On February 6, under the initiative of Mr. Wang, the Marketing Operations Department started thinking and discussing the department’s culture and values. Everyone expressed their steadfastly and did their best to build an indestructible team together;

    On February 11, the company launched the "DingTalk" software to facilitate instant communication through the Internet;

    On February 13, the company’s industrial and commercial registration was changed;

    On February 28, the confidentiality system V1.0 was released;

    Beijing 307 Hospital published the clinical literature on the treatment of cervical cancer with ACTL technology in the fifth issue of "Chinese Journal of Cancer Biotherapy" in 2014, which brought profound impact to ACTL technology;

    In February, after the company’s research and decision, Li Chan of the production department was selected as the "employee star" of the month, and Dong Wenjuan, the production director, was selected as the "manager star" of the month.

  • 2015s

    On March 2, He Aiwen, a QC inspector of the Quality Management Department, joined;

    On March 9th, International Affairs Commissioner Shi Zhuoqi joined the post;

    On March 10, the leaders of the Shenzhen Municipal Science and Technology Innovation Commission and the Finance Committee held a "Breast Cancer Roadmap Implementation Work Conference" in Shenzhen Second People's Hospital in order to strengthen the supervision and management of science and technology projects. The 8 units participating in the meeting included enterprises and universities A total of 10 projects including hospitals and hospitals have carried out project progress and implementation reports, and the company’s two approved technological development and technological breakthrough projects in 2014 have carried out progress reports;

    On March 12, the leaders of the Planning Department of Shenzhen Municipal Science and Technology Commission and the leaders of the incubator visited the company's laboratory and said that the company's laboratory has a good reference significance in the cellular immunotherapy industry;

    On March 12, Yu Jukuan, the cashier of the Finance Department, joined;

    On March 13, the "Attendance Management System V4.0" was released;

    On March 17, Professor Wu Peihong from Sun Yat-sen University Cancer Hospital and leaders and experts from Handan Infectious Disease Hospital visited our company for guidance;

    On March 19, Yang Qi, a technician in the production department, joined;

    On March 20th, leaders and experts from the Second Affiliated Hospital of Xingtai Medical College visited our company for inspection;

    On March 31, Mr. Sun from Anhui Yinzhou Investment Company visited our company and the two parties reached a preliminary cooperation agreement;

    On March 31, the first quarter performance appraisal was launched;

    On March 31, the second issue of "Iskoning Biotherapy Bulletin" was released;

    In March, after the recommendation of various departments and the company's research and selection decision, Ni Chunmei of the Finance Department was selected as the "Employee Star" of the month, and Shi Pengyan of the Project Department was selected as the "Manager's Star" of the month, with encouragement;

    Through arduous efforts in March, the Marketing Operations Department hit a record high in sales.

  • 2015s

    On April 2nd, Peking University Shenzhen Hospital officially applied ACTL technology;

    On April 13, our company signed a market cooperation agreement with Shandong Yishi Kangning;

    On April 17, Li Xiaolan, Human Resources Manager of Human Resources Department, joined;

    On April 20, Zhang Wenli, Technical Support Specialist of the Technical Support Department, joined;

    On April 20, leaders and experts from Guangxi Autonomous Region People's Hospital visited our company for inspection;

    On April 27, Shenzhen Second Hospital officially launched the first application of ACTL technology;

    On April 28th, the company successfully held the "ACTL Technology Multi-center Clinical Trial·Lung Cancer Group Kick-off Meeting" in Guangzhou Baiyun Hotel. The meeting was hosted by Professor Xia Jianchuan and Professor Zhang Li. At the meeting, participating experts actively spoke and put forward opinions and suggestions on the clinical trial plan of the lung cancer group, which greatly promoted the progress of the clinical trial of the lung cancer group and laid a solid foundation for the clinical trial work of the lung cancer group;

    In April, the company decided to select Li Ye from the technical support department as the "Employee Star" of the month, and Niu Zuowen, the manager of the International Department, as the "Manager Star" of the month, with encouragement.

  • 2015s

    On May 4, Li Lu, a technician in the production department, joined;

    On May 8, Director Zhang of the Oncology Department of Weifang Yidu Central Hospital visited our company;

    On May 12, released the latest daily administrative management regulations to strengthen administrative supervision and standardize the internal;

    On May 13, Director Wang of the Department of A and Breast Cancer of Shenzhen Second Hospital visited our company for a visit and exchange;

    On May 13, a disinfection cabinet was added internally to improve the company’s living conditions;

    On May 18, the new antigens G250 and CD269 have been produced and passed the quality inspection, and can be put into clinical use;

    On May 21, the leaders of Jiangsu Tuohong Pharmaceutical Co., Ltd. visited our company;

    On May 25, complete the air conditioning renovation of the open office area to improve the office environment;

    On May 26, the joint marketing operation department organized a knowledge training on "ACTL Technology Clinical Application";

    In May, after the recommendation of various departments and the company's research and selection decision, Shenzhen Experimental Center Wang Hongliang was selected as this month's "Employee Star", and Zhang Mingming from the Quality Management Department was selected as this month's "Manager's Star", with encouragement.

  • 2015s

    The company officially signed a cooperation agreement with BBH Hospital in Thailand, and the company's business entered the international market;

    Experts from the Armed Police General Academy of Guangxi Autonomous Region visited and communicated with the company and discussed ACTL technology and cooperation issues;

    On June 10, issued supplementary regulations on fingerprint attendance;

    On June 11, a Buick GL8 commercial vehicle was added, which further improved the company's reception capacity;

    On June 19, organize ACTL product knowledge test for some personnel;

    On June 29, the company’s balcony newly installed floor cabinets to improve the lunch environment for employees;

    In June, after the recommendation of various departments and the company's research and selection decision, Huang Jialiang was selected as the "employee star" of the month, and Gao Hongji was selected as the "manager star" of the month, for encouragement.

  • 2015s

    On July 6, launch the second quarter performance appraisal;

    On July 13, the People's Hospital of Lancheng District, Jieyang City officially launched the first application of ACTL technology;

    On July 13, Tang Chuyin, an administrative assistant, joined;

    On July 14, Shenzhen Small and Medium Enterprise Service Agency came to the company to conduct an on-site audit. The audit project was the 2015 Shenzhen Small and Micro Enterprise Cultivation Funding Project that the company applied for. The audit work was successfully completed with the cooperation of various departments;

    On July 22, the Marketing Department launched a small-scale clinical research cooperation with Huaqiao Hospital;

    On July 24, after the company's research and decision, Ni Chunmei was appointed as the accountant of the finance department and Huang Jialiang was appointed as the production technology supervisor of the production department;

    On July 29, Nanshan Science and Technology Bureau, industry associations and industry experts came to the company for on-site acceptance work. The acceptance project was the core technology breakthrough project in Nanshan District in 2013. This was the company’s first major on-site acceptance project. Thanks to all departments for their work on the project. Always support and cooperate;

    From July 31st to August 2nd, Shandong Yishi Kangning participated in the National Tumor Biotherapy Summit Forum and the 5th Shandong Provincial Tumor Biotherapy Academic Conference. Manager Tao gave a wonderful explanation of ACTL technology on the spot, and the response was enthusiastic;

    In July, it signed a market cooperation agreement with Dongguan Baolai Biological Technology Co., Ltd., Zhuhai Luda Biological Cell Technology R&D Center, and Guangzhou Yilong Pharmaceutical Biological Technology Development Co., Ltd.;

    In July, after the recommendation of various departments and the company's research and selection decision, Sun Peishu was selected as the "Employee Star" of the month, Gong Yanhao was selected as the "Manager Star" of the month, and Xu Yanwei was selected as the "Sales Star" of the second quarter. Meng became the "Progress Star" in the second quarter, and I would like to encourage it.

  • 2015s

    On August 4, the company organized all employees to conduct fire safety training to improve their daily fire protection awareness and ability to respond to sudden fires;

    On August 10th, Zhuzhou Central Hospital sent a technician to the company for study and exchange;

    On August 10, the Nanshan District Science and Technology Innovation Bureau announced the results of the ninth and tenth batches of acceptance projects in 2015. The results of general R&D projects that the company applied for in 2012 and applied for acceptance in 2014 were “passed”; The result of the core technology breakthrough project applied for acceptance in 2015 was "passed";

    On August 12, signed market cooperation with Shenzhen Ramona Investment Co., Ltd.;

    On August 17, a new version of "Administrative Regulations on the Use of Company Seals and Licenses" was released;

    On August 20, it signed a market cooperation agreement with Qujing Haiers Biotechnology Co., Ltd., and at the same time, signed a scientific research cooperation agreement with Qujing First People's Hospital to further promote the Yunnan market;

    In August, after the recommendation of various departments and the company's research and selection decision, Yan Wu was selected as the "Staff Star" of the month, and Zhang Hui was selected as the "Manager's Star" of the month, with encouragement.

  • 2015s

    92日,项目部、财务部在深圳软件园对公司2013年申请的市科创委项目进行验收答辩,答辩顺利完成;

    915日,深圳市科技创新委员会公示了2015年第三批科技计划项目验收结果,公司2013年申请并于2015年申请验收的创业资助项目结果为“通过”;

    917日,为提升员工的福利水平,公司在现有“五险一金”的基础上,已为全体员工增加了商业保险,体现了公司对每一位员工的关爱及以人为本的理念;

    922日,开展团体商业险的保险责任范围、出险如何理赔等内容培训;

    923日,经公司研究决定,冯雪邮研发助理晋升为研发主管,兼任的总经理助理工作不变;

    924日,公司实施发布午餐补贴制;

    923-25日,2015深圳国际BT领袖峰会和生物/生命健康产业展览会在会展中心举行,公司作为孵化器企业代表之一参展。项目部与各部门同事共同努力,对外展示出公司的良好形象。

  • 2015s

    On October 13, the Shenzhen Science and Technology Innovation Committee announced the 2015 science and technology innovation projects, and the company was among them;

    On October 13, the performance appraisal for the third quarter of 2015 was launched;

    On October 16, the Shenzhen Small Business Service Bureau announced the 2015 small and micro enterprise cultivation project, and the company was among them;

    On October 24th, Mr. Wang led the Marketing Department to successfully participate in the 6th Annual Meeting of the Guangdong Society of Cell Biology and the 2nd Annual Meeting of the Biotherapy Professional Committee of Guangdong Anti-Cancer Association. Manager Tao Yi gave a wonderful speech on ACTL technology , The response was overwhelming, and the on-site consultation was endless. This exhibition has achieved a good promotion effect, which is of great significance;

  • 2015s

    On November 2nd, a warm reminder of “About Handling 2015-2016 Critical Illness Insurance Participation Payment” was issued;

    On November 3, the project department successfully applied to donate newspapers and periodicals to doctors working in Nanshan District;

    On November 9, organized all employees of the company to participate in large-scale fire drills to comprehensively improve personnel fire risk response skills, and conducted drills for evacuation of high-rise buildings;

    On November 11, a market cooperation agreement was signed with Nanning agents in Guangxi, and the market layout was further expanded. Guangxi Armed Police Corps Hospital has rapidly launched the first ACTL technology application;

    On November 12, relevant personnel from the Project Department, Finance Department, R&D Department, and Production Department responded to the Shenzhen Science and Technology Award (Science and Technology Progress Award) that the company applied for in 2015 in Shenzhen Software Park, and the defense was successfully completed;

    On November 30, signed a market cooperation agreement with Hefei Zhikang, and the ACTL technology will be launched in the Hefei Institute of Material Science, Chinese Academy of Sciences and its tumor hospital;

    On November 30, after the company's research and decision, Shi Pengyan was promoted from the project manager to the project director, responsible for the daily management of the project department and the company's network publicity work and personnel training;

    After the recommendation of various departments and the company's research and selection decision, Zhong Jianhui of the Quality Management Department was selected as the "Employee Star" in September, Lu Jing from the Technical Support Department was selected as the "Manager's Star" in September; Huang Jialiang from the Production Department was selected as the "Employee Star" in October "Shi Pengyan from the project department was selected as "Manager's Star" in October;

  • 2015s

    On December 2, the Marketing Department received a visit from the Dean Wei of the Affiliated Hospital of Shanxi University of Traditional Chinese Medicine;

    On December 4, the first case of ACTL treatment was officially launched at the Guangxi General Hospital of the Armed Police Force;

    On December 8, signed a market cooperation agreement with Guangzhou Saiyin;

    On December 9, the Marketing Department received a visit and guidance from Political Commissar Li of the Shenzhen Armed Police General Hospital;

    On December 10, signed a market cooperation agreement with Guangdong Topcon;

    On December 11, the Administration Department organized an outdoor picnic group activity;

    On December 16, Mr. Sun of Anhui Zhikang visited our company and the two parties completed the signing of the scientific research agreement;

    On December 18, the first case of Shenzhen Lemeng officially started;

    On December 24, the marketing department and Shenzhen Peking University Hospital made important progress in cooperation negotiations;

    On December 25, the Administration Department organized the "Christmas" game and the "Handover of Gifts" activities;

    On December 28, the project department completed the declaration of medical device titles for the company’s qualified employees;

    On December 29, the 2015 fourth quarter performance appraisal and annual performance evaluation were launched;

    On December 30th, the leaders of Shenzhen Science and Technology Innovation Committee came to our company to conduct research on the scientific and technological progress award that the company applied for in 2015. With the cooperation of various departments, the research work was successfully completed;

    After the recommendation of various departments and the company's research and selection decision, Feng Xue of the R&D department was selected as the "Employee Star" in November, and Li Fan of the R&D Department was selected as the "Manager Star" in November;

  • 2014s

    On January 2, the company purchased a new Santana official vehicle.

    On January 8, according to the notice of the Shenzhen Municipal Science and Technology Innovation Commission, the 2012 project mid-term defense was completed in the virtual university park.

    On January 9, the performance appraisal for the second half of 2013 and the annual general evaluation were completed, and Spring Festival gifts were issued.

    On January 13, all the staff of the Marketing Operations Department participated in the 2013 sales summary meeting. Everyone made a systematic and comprehensive summary of the work in their own regions. Mr. Wang made expectations for the work of the department in 2014, and all regional managers maintained High morale.

    On January 13-15, organize the company's annual meeting and two-day tour of Heyuan Hot Spring.

    On January 16, the third batch of Shenzhen venture capital inferior project contracts that the company applied for in 2013 was reviewed and approved with a capital of 500,000.

    On January 17, the design of Kexing site completed the final draft of the layout plan.

    On January 20th, Cheng Ming, Regional Manager of Marketing Operations Department-South China joined the company.

    On January 23, the company signed a cooperation agreement with Guangdong Red Sun Company.

    On January 28, the first trial of graphic design was completed.

    In January, Mr. Wang visited the agents who had performed well in 2013 in South China and put forward their work expectations.

  • 2014s

    On February 10, the second meeting of the company's decoration design plan review was held to promote the steady progress of the design work.

    On February 10, the salary structure adjustment and the "Attendance Management System" were updated to version V3.0.

    On February 11, Li Aiqing, a cell culture technician in the three production departments, became a regular employee.

    On February 12, Xu Yueying, a cleaning staff member of the Administration Department, joined the company.

    On February 18, the "Employee Benefit Management Measures V2.2" was released.

    On February 18, Zhong Jianhui, a QC inspector of the Quality Management Department, became a regular employee.

    On February 20, the Annual Leave Management Measures V1.0 was released.

    On February 20th, every Tuesday after get off work hours, the company organized a regular indoor badminton activity to encourage all employees to participate actively to improve their physical fitness.

    On February 24, the production department's performance appraisal program V2.0 was implemented on a trial basis.

    On February 24, the performance appraisal program V2.0 of the Quality Management Department was implemented on a trial basis.

    On February 24, Zhang Xiaoyun, Technical Support Specialist of the Technical Support Department, joined the company.

    On February 27, the design drawings were reviewed by three parties to determine the details of the construction drawings.

    Under the leadership of Mr. Wang, a cooperation agreement was signed with Zhuhai Luda Hospital. Zhuhai Luda Hospital officially introduced ACTL technology, filling the gap in Zhuhai area.

    The ACTL project in Anyang area of Henan market and Handan area of Hebei market has been officially launched, and the first clinical application of ACTL technology has been carried out in the two places.

    The company brochure has been revised again under the guidance of Professor Liu, with more detailed data and richer information. All departments are welcome to read it.

    The sales and payment collection of the Marketing Operations Department have improved significantly compared with last year. Mr. Wang expressed his thanks to all departments for their strong support!

  • 2014s

    On March 6, a drawing confirmation letter was issued, and the Kexing decoration project entered a new stage.

    On March 10, the company launched a sports and cultural project for employees, and currently has organized a regular badminton activity every Tuesday.

    On March 10th, the company participated in the Nanshan District Science and Technology Commissioner Meeting as one of the establishment units of the core technology breakthrough project in Nanshan District in 2013. The head of Jizhen District of Nanshan District attended and delivered a speech.

    On March 11, according to the science and technology special commissioner system of the core technology breakthrough project in Nanshan District, Professor Tu Pengfei, the science and technology commissioner of Peking University School of Pharmacy who guided our project, visited the company.

    On March 12, administrative assistant Zhou Yanran entered the post.

    On March 12, Xu Yueying, a cleaner, became a regular employee.

    On March 17, Dr. Yang Jinxing, the manager of the Medical Department, joined the company.

    On March 17, organized some personnel from the Production Department and the Quality Department to participate in the "Medical Device Industry Internal Auditor" training.

    On March 24, the problem of Kexing's capacity expansion was solved, saving 200,000 yuan in the first year's capacity expansion fee and monthly basic charges.

    On March 25, organized company employees to visit the new office space of Kexing Science Park.

    On March 26, the site of Kexing Science Park was reviewed and approved by the property management party, and construction began.

    On March 27th, the 44th class "ADC" trademark applied by the company was successfully registered and was awarded the "Trademark Registration Certificate" by the Trademark Office. Currently, the company holds 10 registered trademarks.

    A business cooperation agreement was formally signed with the People’s Hospital of Huadu District, Guangzhou. The development of this hospital was rugged and lasting for several months. The stories that happened during the development process were impressive. The development of each hospital included Mr. Wang and a large number of employees in the marketing operation department. The hard work has contributed greatly to the company's development.

    Signed a cooperation agreement with Guangzhou Zhongtai Pharmaceutical Technology Co., Ltd.

  • 2014s

    On April 1, the regional manager-South China Tao Yi joined.

    On April 3, Kexing Decoration Drainage Point drilled holes and negotiated with the tenants downstairs to reach an agreement to obtain one point to greatly improve the drainage differential pressure problem.

    On April 8th, the performance appraisal for the first quarter of 2014 was launched and ended successfully on the 17th.

    On April 9th, a physical examination of employees was organized, which was completed at the end of the month.

    On April 9, the company announced that all employees are not allowed to inquire about the price of raw materials.

    On April 11, the office area wall erection project was completed, and the original office furniture supplier provided deck potential points and provided preliminary handling plans.

    The company joined the Shenzhen Life Science and Biotechnology Association led by the Shenzhen Municipal Science and Technology Commission in 2012. It was a member unit at that time; this year, the Science and Technology Commission and the Association sincerely invite the company in view of the company’s outstanding contributions and social influence in the industry Become a council member of the association. At present, the association has more than 100 members and more than 20 director-qualified units. The company will become the youngest director unit in the association.

    On behalf of the company, Shi Pengyan from the project department was invited to participate in the loan-to-lending conference hosted by the director of Nanshan Science and Technology Bureau. Participants included banks, venture capital institutions, and listed companies. At the meeting, Shi Pengyan represented the company as a representative of outstanding enterprises in Nanshan within 5 years and actively spoke.

    The company's multi-center clinical trial has entered the preparatory stage and is expected to be officially launched at the end of May.

    Since the signing of the Zhuhai Luda Hospital, two foreign cases have been successfully treated with ACTL technology, and tumor markers have been significantly reduced.

    Mr. Wang welcomed Guangxi agents and experts from the Cancer Hospital to visit the company and introduced ACTL technology to the experts from the Cancer Hospital.

  • 2014s

    On May 3, according to the 2014 project defense notice of the Shenzhen Science and Technology Innovation Commission, Professor Liu, as the project leader, made a defense in the software park. Dr. Yang from the Medical Department and Shi Pengyan from the Project Department accompanied him.

    On May 5, the "Administrative Measures for Travel Expenses V2.2" was released.

    On May 8, our company sincerely invited leaders and experts from the Central Hospital of Shenyang Medical College to visit and guide the company.

    On May 12, our company signed a formal business cooperation agreement with Shenzhen Aobejian Biotechnology Co., Ltd.

    On May 12th, our company and Life Length Health Management Co., Ltd. held an academic exchange meeting. The two sides conducted academic discussions on ACTL technology and PreMiD technology.

    On May 12, Zhou Yanran, the administrative assistant, became regular in advance.

    On May 14, the company's internal processing notice was released.

    On May 14, the personal commendation notice of Liao Juan was received.

    On May 14th, the Marketing Operations Department actively cooperated with the major projects of the Ministry of Health and completed the collection of feedbacks from various hospitals on clinical trial programs.

    On May 16, our company signed a formal cooperation agreement with Shanghai Yixin Biotechnology Co., Ltd. to achieve a new breakthrough in the Shanghai market.

    On May 19th, our company signed a business cooperation agreement with Century Aiheng Biotechnology (Tianjin) Co., Ltd.

    On May 22, the investment director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. visited our company.

    On May 23, collect and release the "Dragon Boat Festival" holiday gifts.

    On May 26, the Market Operations Department officially began to improve the national regional patient screening system. The Marketing Operations Department successfully completed the sales task in May, and the amount of money returned hit a new high this year;

    On May 31, the Shenzhen Municipal Science and Technology Innovation Commission announced the list of special projects for the development of the biological industry in 2014. The company's project "Development of a new generation of targeted breast cancer cell immunotherapy technology" was among them.

  • 2014s

    On June 27th, the project department participated in the International Symposium on Immune Cell Therapy and the Second Biomedicine Summit Forum held in Shenzhen Advanced Institute of Chinese Academy of Sciences.

    Led by the Life, Health and Biotechnology Division of Shenzhen Science and Technology Innovation Commission, the breast cancer industry roadmap hosted by the Life Science and Biotechnology Association held the first meeting to discuss, and the project department was invited to participate on behalf of the company. Participants included Wanle Pharmaceutical, Microchip Technology, Shenzhen Second People's Hospital, Shenzhen University Research Institute, and Southern Medical University. The participating units are all influential units in Shenzhen Cancer Research.

  • 2014s

    On July 3, with the concerted efforts of all employees, the company moved from the original office address at No. 19 Langshan Road to the new office space on the 16th floor of Unit A1 of Kexing Science Park. The total area of the company is 1941 square meters.

    On July 6, the company solemnly held a housewarming ceremony at the new venue, starting a new chapter since then.

    On July 8, the 2014 employee provident fund and social security base were adjusted in accordance with national policies.

    On July 10, the "Administrative Measures for Parking Fee Subsidy in Kexing Park V1.0" was released.

    From July 17 to 28, the “2014 Second Quarter Performance Appraisal” was launched and completed.

    From July 23-28, according to the company's development needs, several appointments and organizational structure adjustments were made;

    From July 24 to 25, the “Market Work Summary Conference for the First Half of 2014” was held, and a two-day seaside vacation tour of “Huidong Shuangyue Bay” was arranged.

    On July 28th, administrative assistant Julie joined.

    On July 29, organized company colleagues to participate in the farewell party for Liao Juan's remains.

  • 2014s

    On August 4, Feng Xue was appointed as "Assistant to the General Manager".

    On August 4, Cao Jie's personal commendation announcement was issued.

    On August 7, Professor Liu and the project department participated in the 2014 Nanshan District Cell Therapy Technology Research Institute project defense that the company applied for, and the defense was successfully completed.

    On August 11, "Attendance Management System V3.1" was released.

    On August 11, Sun Peishu, project specialist of the project department, joined the company.

    On August 13, our company and Ningxia agents formally signed a market cooperation agreement.

    On August 15, the "Employee Benefit Management Measures V2.3" was released.

    On August 19th, Academician Zeng Yixin sent a letter in his busy schedule to express his expectation for excellence in the ACTL SOP research plan; on August 19th, Meng Mengmeng, a technician in the production department, entered the post.

    On August 20th, Director Qiu of the Shenzhen Municipal Science and Technology Commission, Department of Life Sciences and Biotechnology Chen, Guo Bo, and Minister of Incubator Hua Wei came to the company to visit and guide and listen to the company's development needs and suggestions.

    August 21-24, went to Guangzhou for the conference work of "ACTL Technology Multi-center Clinical Trial Program Seminar".

    On August 22, the director of Tianjin Cancer Hospital came from afar to visit our company.

    On August 26th, Professor Liu, the Project Department, and the Finance Department conducted an acceptance defense on the company's 2012 Science and Technology Commission project in Shenzhen Software Park.

    On August 29th, Shenzhen Life Science and Biotechnology Association led Director Li of the People's Hospital, Beike Biotechnology and other companies into Yishi Kangning for visits and exchanges.

    Affected by policy factors, the Marketing Operations Department successfully completed the full-year sales target in August during the most difficult period this year.

    Our company signed a market cooperation agreement with Shanghai Zhenyuan Biotechnology Co., Ltd.

    In August, the shooting of the company's promotional video was officially launched.

  • 2014s

    On September 3rd, a group of 4 leaders from Nanshan Science and Technology Bureau visited the company for an on-site inspection, and the inspection project was an innovation organization establishment project applied by the company.

    On September 3, the project department went to the Shenzhen Development and Reform Commission to participate in a joint meeting of the three committees of the Science and Technology Innovation Commission, the Economic and Information Commission, and the Development and Reform Commission to discuss the development needs of the cell therapy industry with industry units.

    On September 4, Niu Zuowen, International Customer Service Manager of the International Department, joined;

    On September 9, experts from Zhuzhou Central Hospital visited our company;

    On September 9, Professor Liu and Project Department Shi Pengyan were invited to participate in the press conference of the National Bio-Innovation Fund kick-off meeting held in Wuzhou Hotel. Vice Minister of Science and Technology and Mayor Xu Qin attended and delivered speeches.

    On September 9, Ni Chunmei, the cashier of the Finance Department, joined;

    On September 10-12, the 2014 Shenzhen International BT Summit and Biological/Life Health Industry Exhibition were held at the Convention and Exhibition Center. The company participated as one of the representatives of incubator companies. During the exhibition, I am honored to lead Mayor Xu Qin and Secretary Wang Rong to the company booth, and actively show the company's development and ACTL technology to Secretary Wang and Mayor Xu in the project department, production department, technical support department, marketing department, R&D department, etc. With the joint efforts of the department's participating colleagues, ISKCON has demonstrated a good image of the company!

    On September 11, organize Kingdee WISE product promotion conference;

    On September 12, organize Kingdee WISE and CLOUD product comparison meeting and internal discussion;

    On September 12, "Company Organization Chart V7.0" was released;

    On September 14, the Marketing Operations Department held an August work summary meeting and deployed key tasks in the next phase;

    On September 17, the financial and social security cards were replaced uniformly;

    On September 22, organized the ERP system WISE software and the company demand exchange meeting.

    On September 23, the company completed the procedures for changing the registered address of the business license, organization code certificate, and tax registration certificate.

    On September 28, in accordance with the Nanshan District policy, the project department has successfully applied for the company as a pilot enterprise for the settlement of talents in Nanshan District, and actively applied for housing subsidies to the Bureau of Housing and Urban-rural Development for eligible employees of the company.

    In September, experts from Peking University Shenzhen Hospital visited our company and conducted academic exchanges;

    Market Operations Department’s performance in the third quarter of 2014 hit a new high, exceeding the full-year mission;

  • 2014s

    On October 8, our company signed a market cooperation agreement with Yunnan Kangxiang Pharmaceutical Co., Ltd., and the clinical application of ACTL technology in Yunnan Cancer Hospital was officially launched;

    On October 8, Xie Chunhua, Sales Supervisor of Marketing Operations Department, joined the company;

    On October 11, organized a Q&A meeting for the content of the ERP module of the production system;

    On October 11, the Marketing Department held the third quarter work summary meeting and deployed key tasks for the fourth quarter;

    On October 14-17, the third quarter performance appraisal will be carried out;

    On October 15th, Shenzhen Science and Technology Commission Company was listed as the second batch of high-tech enterprises in Shenzhen in 2014;

    On October 21, the "Inventory Management Flow Chart V1.2" was released internally and started to execute;

    On October 21, the project department participated in the 4th meeting of Shenzhen Breast Industry Roadmap. Director Li Zhenguang and Dr. Guo Liang of the Science and Technology Innovation Committee attended the meeting. The participating units were influential companies, hospitals, universities, etc. in the industry;

    On October 22, the project department completed the online filing of Shenzhen SMEs;

    On October 23, the regional manager of the marketing operation department-Southwest Quan Haizong joined;

    On October 26, the Marketing Department held a weekly meeting to mobilize the deployment of the previous work sprint and start planning for next year's work;

    On October 27, complete the company's front desk poster and publicity column;

    On October 28th, the project department completed the application for the Nanshan District talent settlement subsidy for the employees under the company regulations;

    On October 30, organized and held the ERP construction project kick-off meeting;

    On October 30, the company shot a promotional video on site;

    On October 31, start the preparations for the 2014 Thailand Tourism Event;

    The market operation department continued to maintain steady performance in October, with annual sales and payment collection being 2.5 times and 3.7 times the same period last year, setting a new historical record again;

    The last on-site audit of IS09001 certification was completed, and the company obtained the IS09001 certification recognized by the National Certification and Accreditation Administration Committee.

  • 2014s

    On November 1, the Marketing Department and Technical Support Department participated in the Fifth Guangdong Cell Biology Symposium and represented the company in an exhibition;

    On November 8, Professor Liu led the Marketing Operations Department to participate in the 2014 Anhui Seminar on Translational Medicine and Individualized Treatment of Major Diseases of Lung Cancer. At the conference, Professor Liu’s academic speech and ACTL technology aroused a strong response;

    On November 18th, our company signed a market cooperation agreement with Anhui Fuyang agents;

    On November 20th, our company and Peking University Shenzhen Hospital signed a memorandum of cooperation on ACTL technology. At the same time, Professor Liu was specially hired by Peking University Hospital as a guest professor;

    On November 21, according to the notice of the Shenzhen Municipal Science and Technology Commission, Professor Liu defended the company's technical research topics, and the heads of the project department and the finance department participated together;

    On November 21, the installation of dehumidification equipment in the clean area of the laboratory started;

    On November 24, Yan Wu, Technical Support Supervisor of the Technical Support Department, joined;

    On November 25, release the relevant notice of the 2014 Thailand Annual Meeting;

    On November 26, Lu Yuping, vice chairman of the Nanshan District CPPCC, accompanied by Wang Ming, chairman of the Nanshan District Association for Science and Technology, led a delegation of Nanshan District CPPCC members to inspect our company. Chairman Lu is very interested in the company's technology, and at the same time places hope for the company's development;

    On November 27, the "Employee Benefit Management Measures V3.0" and "Attendance Management System V3.2" were released;

    On November 28, the project department received the Shenzhen High-tech Enterprise Certification Certificate;

    With the efforts of all my colleagues in the Marketing Operations Department, the Marketing Operations Department achieved gratifying results in November, setting new historical records again.

  • 2014s

    On December 1, confirm the batch list of Thailand's annual convention tourism;

    On December 2, Puning People’s Hospital formally launched the first clinical application of ACTL technology, marking a good start for the development of Eastern Guangdong;

    On December 4th, participated in the campus job fair and interview of Shenzhen Vocational College;

    On December 5, the Shenzhen Municipal Science and Technology Commission announced the sixth batch of major technical research topics in 2014, and the company's projects were among them;

    On December 11, launch the 2014 fourth quarter performance appraisal and annual general evaluation;

    On December 12, the application of ACTL technology in Taiyuan Tumor Hospital was officially launched;

    On December 15, Cao Yang, R&D Specialist of the R&D Department, joined;

    On December 17, experts and leaders from Shenzhen People's Hospital visited our company;

    On December 19th, leaders and experts from Kunming General Hospital of Chengdu Military Region of Yunnan Regional Manager Association, Yan'an Hospital of Kunming City, Second People's Hospital of Yunnan Province visited our company;

    On December 22, the special commissioner of Nanshan Science and Technology Bureau, Professor Tu from Peking University, came to the company to guide the core technology breakthrough project. The leaders of Nanshan Science and Technology Office participated as the special commissioner affairs cooperation unit;

    From December 24th to 25th, organize "Christmas" games and "exchange gifts" activities;

    On December 29th, our company signed a market cooperation agreement with Shenzhen Sugo Biotechnology Co., Ltd.

    In December, the first issue of ISKCON’s Biotherapy Bulletin was issued;

    In 2014, with the efforts of all my colleagues, the marketing department's annual performance created the best record in history. Sales and payment collection achieved leaping year-on-year growth, opening an account for ISKCON to create a new chapter in a bright future.

  • 2013s

    Xu Yanwei was appointed as the assistant to the general manager on May 14. The original position remains unchanged.

    On May 15, the original "registered project department" was adjusted to the "R&D department", and Shi Pengyan was transferred to this department.

    On May 25th, the company successfully reached a cooperation with the People's Liberation Army 307 Hospital and began clinical application treatment.

    On May 25-26, he participated in the academic seminar on the establishment of the Shenzhen Biotherapy Association. Professor Liu gave a keynote speech and received enthusiastic responses. The influence of ACTL technology in Shenzhen has been further strengthened.

    On May 28, the Human Resources Department launched the company-wide work analysis and interviews, conducted all-staff interviews from June 4th to 9th, and conducted a summary report on June 19th.


  • 2013s

    On June 3, Mr. Wang Kun formally joined the company as the director of the marketing operation department. A warm welcome.

    On June 5th, the mayor of Nanshan District and the director of Nanshan District Science and Technology Bureau came to our company for investigation and investigation of the core technology projects declared by our company in 2013.

    On June 17, the company's organizational structure was adjusted. The original "Clinical Operation Department" was adjusted to the "Market Operation Department", and the "Technical Support Department" was added under the Production Department. Lu Jing, Hu Jingjing, and Cao Jie were transferred to this department.

    This month, the company has processed the funding application in accordance with the requirements of the municipal science and technology committee and the finance committee for the 2012 project funding. At present, the regulatory bank has completed the first 90% of the project funding, and the other 10% of the project funding needs to be completed after the project is accepted.


  • 2013s


    The company's new products PAP and MAGE-3 have begun mass production.

    The technical transformation of ACTL's third-generation technology has begun, and it is currently in the stage of experimental demonstration of the feasibility of technological improvement. The realization of ACTL third-generation technology will further reduce production costs and increase the market competitiveness of ACTL technology.

    The ACTL technology research and development projects for two new antigens have been launched. The successful research and development of these two projects will play a role in the treatment of lung cancer and the reversal of tumor resistance, and has huge market potential.

    A variety of multi-target CTL technology for tumor cell immunotherapy clinical research expert advisory meeting was successfully held in Beijing. Participants discussed the "Multiple multi-target CTL technology for tumor cell immunotherapy clinical research application" declared to the Ministry of Health and solicited Experts suggest to prepare for smooth declaration. The company introduced the preclinical research and safety evaluation of ACTL technology to experts. Experts gave a good evaluation of the preclinical research and related clinical data of this technology, and put forward constructive opinions.

    On July 8, Feng Xue, assistant of R&D department, joined the company;

    On July 22, Cai Haisong, a technician of the third production division, joined;

    On July 26, the "Technical Support Department" was adjusted to a subordinate department of the "Market Operations Department", and the employees in the department were adjusted simultaneously;

    On July 29, the company's website was updated and entered normal operation.

    Cooperated with an agent in Hubei, and the contract has been signed.

    The company's contracted hospital Tianjin Cancer Hospital began to admit patients.

    The director of Zhuzhou Central Hospital and his entourage are expected to visit the company in August and conduct technical exchanges.


  • 2013s

    On August 16, Tianjin Cancer Hospital launched the first case of ACTL technology to treat patients with colorectal cancer. The company arranged for Cao Jie, a colleague of the technical support department, to be responsible for the technical guidance and training of laboratory cell culture. Through the full follow-up of the first case, familiar with the clinical process in the hospital, paving the way for the treatment of expanded cases in the future;

    The commercial cooperation of Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine has officially entered the hospital approval process, and a cooperation agreement will be signed in the short term.

    On August 6, the salary grading and sales incentive plan of the Marketing Operations Department was released, which has been publicized and implemented within the department.

    On August 8, the work summary and performance appraisal for the first half of 2013 were carried out, and all the appraisal results have been fed back to the department.

    On August 15, Wang Yuan, a technician in the third division of production, joined the company.

    From August 12th to August 13th, the director of Zhuzhou Central Hospital and his entourage visited our company. They spoke highly of our company's ACTL technology and expressed their willingness to cooperate.

    Shaanxi Xijing Hospital signed a cooperation agreement with our company.

    In August, the company signed a cooperation contract with two agency companies.

    The company officially launched scientific research cooperation with Anhui Medical University.


  • 2013s

    On September 3, Nanshan Science and Technology Bureau announced that the "ACTL Targeted Cellular Immunotherapy Technology Development and Application" declared by our company was shortlisted for the "2013 Nanshan District Core Technology Breakthrough Funding Program Project";

    On September 9th, the regional manager of the Marketing Operations Department—East China, Dai Zhong entered the post, warmly welcome.

    On September 10th, the Marketing Operations Department, Operations Assistant, and Hangren joined the company. A warm welcome.

    On September 10, the company received a new business license;

    On September 13, Xu Yanwei from the Marketing Operations Department handed over the job of "General Manager Assistant" to Lai Weijie in the Administration Department due to market work needs.

    On September 23, the new product survivin antigen entered mass production, passed the quality inspection, and has been put into clinical use. The company's products have added another member.

    On September 23, the marketing operation department, the regional manager-Northeast, Zhu Yan warmly welcomed the entry.

    The company reached a cooperation intention with Henan Anyang Cancer Hospital.

    Beijing ACTL's high-end intelligence club was approved by the state, and preparations for the establishment were officially started.

    Officials from the Beijing Ministry of Health visited Shenzhen to inspect our company.

    Our company has reached a cooperation agreement with Hebei agents and has officially started business.

    The company signed an agency contract with an agent in Anhui Province.

    The company signed a commercial cooperation agreement with Zhuzhou Central Hospital.

    The company and Shenzhen Second Hospital formally reached a cooperation intention.

    The company signed a commercial cooperation agreement with Nanfang Hospital, and the company continued to expand its business to a new level.


  • 2013s

    The company successfully established the 2013 Nanshan District Core Technology Breakthrough Project to complete the project contract signing and funding procedures, and the funding can be completed before the end of the year.

    The 2013 Shenzhen Science and Technology Innovation Commission's small and micro entrepreneurial funding project that the company applied for in September has been publicized on the official website of the Technology Innovation Commission.

    The three production units, Cai Haisong and Wang Yuan, have worked hard and performed well during the probation period, and the company has allowed them to be positive on October 1st and November 1st to encourage them.

    Due to his hard work and outstanding performance during the probation period, Mr. Hang Ren of the Marketing Operations Department allowed the company to advance on November 1st to encourage him.

    On October 10, the company's organizational structure and personnel were adjusted, the "Purchasing and Treasury Management Department" was added, and Gao Hongji was appointed as the purchasing manager. The production department Zhang Hui and Gong Yanhao concurrently served as the department's treasury management.

    On October 14, the adjustment of the social security payment base for all employees of the company started. The adjustment for local employees in Shenzhen was completed on the 18th, and the adjustment for employees in remote locations will be completed in mid-November.

    On October 15th, the relevant laboratory staff was organized to carry out the "two-and-a-half hepatitis B" test and hepatitis B vaccine injection.

    On October 16, the adjustment of the production department's performance appraisal plan was completed, and it has been launched and implemented.

    On October 17, the strategy for handling some exit documents was released, including Hong Kong and Macau permits, passports and individual travel to Taiwan.

    On October 28th, Liu Xinmei, a cleaning staff member of the Administration Department, entered the post and gave a warm welcome.

    Congratulations on the sales performance of the Marketing Operations Department in October.

    Special praise to Shi Pengyan for her outstanding performance in project application and her significant contribution to the company's many government projects.


  • 2013s

    Warmly welcome 2 new employees to join the ISKCONN family. They are: Li Aiqing, a technician in the third production division, joined on November 11; Zhong Jianhui, a QC inspector from the Quality Management Department, joined on November 18.

    November 10, 1 million yuan of funding for the core technology breakthrough project in Nanshan District was received

    On November 12, the "Quality Management Department Performance Appraisal Program V1.0" was released and implemented.

    On November 14, the conference room of the Shenzhen headquarters held a lecture on hepatitis virus, human papillomavirus (HPV), HIV (HIV), Treponema pallidum, etc., to popularize the characteristics of these infectious viruses and knowledge about prevention and treatment.

    On November 18, the company’s organizational structure and personnel adjustments: the addition of a "project department", adjustment of Shi Pengyan to the project department, appointment of Shi Pengyan as the project manager of the project department; appointment of Li Fan as the R&D manager of the R&D department; appointment of Dong Wenjuan as the production manager of the production department.

    On November 18, the Guangzhou agent successfully signed the contract and produced the first normal treatment.

    On November 19, an independent "handover room" was set up in the company, which raised the level of the process supervision mechanism.

    On November 29, the Northeast Regional Cooperative Hospital successfully signed the contract. The Zhejiang agent successfully signed the contract.

  • 2013s

    The commercial cooperation agreement with Shandong was signed on December 10th.

    On December 15th, the company organized the "Christmas Gifts" activity.

    On December 16, the Human Resources Department signed an annual recruitment cooperation contract with China Talent Hotline.

    The commercial cooperation agreement with Henan was signed on December 17th.

    On December 19, the company organized all employees to take an ACTL product knowledge test.

    The commercial cooperation agreement with Hubei was signed on December 20.

    On December 28th, the company organized a New Year's activity called "Bright Farm Day Tour".

    On December 31, the 2014 sales policy of the Marketing Operations Department was updated, and it has been released and implemented internally.

    On December 31, the Marketing Operations Department completed the 2013 sales task with outstanding results.

Qualification & Honor

  • Year Award/Certificate Issued by Treatable Conditions
  • 2014-2017 Shenzhen High-tech Enterprise Certificate Shenzhen Science and Technology Innovation Committee Honest Enterprise Read
  • 2015-2017 High-tech Enterprise Certificate Shenzhen Science and Technology Innovation Committee Honest Enterprise Read
  • 2016-2017 Shenzhen Science and Technology Progress Award Certificate Shenzhen Municipal People's Government Honest Enterprise Read
  • 2016-2019 Enterprise Credit Rating Certificate Beijing Guofutai Credit Management Co., Ltd. Honest Enterprise Read
  • 2014-2017 Quality management system certification Guangdong Quality Inspection Zhongcheng Certification Co., Ltd. Honest Enterprise Read
  • 2015-2018 Environmental management system certification Guangdong Quality Inspection Zhongcheng Certification Co., Ltd. Honest Enterprise Read
  • 2015-2018 Occupational health and safety management system certification Guangdong Quality Inspection Zhongcheng Certification Co., Ltd. Honest Enterprise Read

Team of Experts

Yong LiuProf.
Chief Scientist

Chief scientist of ACTL targeted anti-tumor immune technology. Graduated from Zhejiang Medical University with a doctorate degree. In 1998, he went to the United States and received funding from the National Natural Science Foundation of China, the Natural Science Foundation of Zhejiang Province, the National Institutes of Health (NIH), the American National and Arkansas Cancer Society and other scientific research projects.


self introduction:

Under the tutelage of Paul Hermonat, an international authority in the field of adeno-associated viruses, and the 2011 Nobel laureate Ralph Steinman

Served as Deputy Director of the Gene and Biotherapy Center of the Rockefeller Cancer Center at the University of Arkansas School of Medicine

Served as Deputy Director of the Immunotherapy Center of the Cancer Center of Stanford Bridge University School of Medicine (in preparation)

PhD, Zhejiang Medical University

Postdoctoral fellow, Arkansas Medical University, Assistant Professor, Associate Professor, Professor, Clinical Lecturer

U.S. and Hong Kong medical oncologist license

Inventor of ACTL Technology, Chief Scientist of ISKCON

Distinguished, visiting or honorary professors from universities, research institutions and hospitals in China, Hong Kong, Japan, etc.

Member of the Oncology Biology and Immunotherapy Committee of the American Society of Clinical Oncology (ASCO)

Editors or full-time reviewers of several international basic and clinical journals related to tumors, immunity, viruses, and molecular biology


Major achievements:

Professor Liu Yong is the first to prove that the non-pathogenic Recombinant Adeno-associated Virus (rAAV) can effectively infect human dendritic cells, overturning the previous belief that Adeno-associated Virus (AAV) The view that it cannot be infected or the infection efficiency is extremely low. In the study, it was proved that rAAV-infected dendritic cells can effectively induce cytotoxic T lymphocytes with powerful targeted killing of malignant tumor cells. Subsequently, related clinical trials and research were carried out and succeeded. On this basis, an anti-tumor targeted cellular immunotherapy technology based on recombinant adeno-associated virus (AAV-DC-CTL, ACTL) was established. The clinical application of ACTL technology has achieved satisfactory results. The scientific research team led by Professor Liu Yong promoted the AAV vector from the third generation to the current eighth generation vector within a few years. The prepared rAAV virus not only has high titer, strong activity and high purity, but also fully meets the needs of clinical treatment. Moreover, the ACTL technology has been advanced from the first generation to the fourth generation, and the fifth and sixth generation ACTL technologies are under development. Over the past ten years, a total of more than 60 academic papers have been published, and several awards issued by the US NIH, ASCO, and the Cancer Society have been awarded. It has 5 US and international patents, 8 Chinese patent authorizations and more than 10 international and The Chinese patent is pending. The established Shenzhen Yishi Kangning Biotechnology Co., Ltd. has successively obtained Shenzhen High-tech Enterprise, National High-tech Enterprise, Shenzhen Science and Technology Progress Award, International Biotechnology Achievement Gold Award, and ISO9001 3 quality management system certifications within 4 years, and has obtained several government Funded R&D projects. In 2016, it was approved by the National Health and Family Planning Commission and was the first to carry out formal Phase II/III clinical trials for non-small cell lung adenocarcinoma and prostate cancer. The first large-scale targeted cellular immunotherapy clinical trial approved by this country not only provides clinical big data for precision medicine, but also puts my country at the international leading level in related fields.


main honor:

High-end foreign expert of China State Administration of Foreign Experts Affairs in 2011

2011 Beijing-Tianjin-Hebei high-tech leading talent

Talents of Tianjin "Thousand Talents Plan" in 2010

2013 Guangdong Science and Technology Leading Talent

2014 Shenzhen high-tech leading talent

2015 Talents of Hebei Province "Hundred Talents Program"

2016 Jiangsu 321 Engineering Talent

Ralph Steinmanprofessor
Former Professor of Rockefeller University

Laureate of the late 2011 Nobel Prize in Medicine

Former Professor of Rockefeller University (Rockefeller University)

Former member of the American Academy of Sciences and American Academy of Medicine

Professor Steinman is an internationally renowned immunologist and cell biologist. Because he was the first to discover dendritic cells (DC, dendritic cells), an antigen-presenting cell that plays a key role in the immune system, and reveals its function, he is known as the father of contemporary immunology. The discovery of dendritic gate cells is the most important achievement of immunology in the twentieth century. It is a landmark milestone in medicine, biology and immunology, laying the foundation for the rapid development of contemporary immunology and applied research.


Michelleprofessor
Director, Cancer Center, Stanford University Schoo

Director, Cancer Center, Stanford University School of Medicine


      Professor of Oncology, Professor of Hematology

      President of the American Society of Hematology

      Professor Mitchell has been engaged in anti-tumor molecular targeted therapy and immunotherapy for a long time, and has created several new therapies for the treatment of leukemia. He is an internationally renowned oncologist.


Shu Yongqianprofessor
Director of Oncology Department, Jiangsu Provincia

Director of Oncology Teaching and Research Office of Nanjing Medical University, Director of Jiangsu Translational Cancer Center for Clinical Medicine, Deputy Director of Cancer Research Center of Nanjing Medical University. He is the academic leader of oncology in Jiangsu Province. He has published more than 70 research papers, edited 3 monographs, and won provincial and departmental scientific and technological achievements four times. In recent years, he has been mainly engaged in the research of new targets for personalized diagnosis and treatment of non-small cell lung cancer, early screening of gastric cancer and genetic strategies for personalized treatment, and molecular immunotherapy of malignant tumors.

Administrative positions:

Director of Oncology Department, Jiangsu Provincial People's Hospital

Director of Oncology Teaching and Research Office, Nanjing Medical University

Director of Jiangsu Cancer Translational Clinical Medicine Center

Deputy Director, Cancer Research Center, Nanjing Medical University


Social work:

Chairman of Jiangsu Provincial Committee of Biological Diagnosis and Therapy

Chairman of the Committee of Tumor Immunity, Jiangsu Society of Immunology

Chairman of the Professional Committee of Tumor Biological Diagnosis and Treatment of Jiangsu Biotechnology Association

National Committee of Chinese Medical Association

CSCO Executive Committee

Vice Chairman of National Cancer Hyperthermia Alliance

Member of the International Lung Cancer Federation Professional Committee

Member of the Standing Committee of the Gastric Cancer Committee of the Chinese Anti-Cancer Society

Executive Director of Jiangsu Society of Immunology

Executive Director of Jiangsu Anti-Cancer Association

Vice Chairman of Nanjing Cancer Society

Executive Director of Jiangsu Anti-Cancer Association


Talent title:

Provincial "333" second-level training object

Leading Talents of Oncology in Jiangsu Province

Head of Jiangsu Oncology Innovation Team


Awards:

China Medical Science and Technology Third Prize: Research on the treatment and prognosis of non-small cell lung cancer guided by molecular markers

Second Prize of Jiangsu Science and Technology Progress Award: The role of related gene detection in early gastric cancer screening and individualized treatment

Third Prize of Chinese Medical Science and Technology: Research on genetic strategies for early screening and individualized treatment of gastric cancer

First Prize of Jiangsu Medical Science and Technology Award: Basic and clinical research on the regulation of apoptosis-related genes in malignant tumors

First Prize of Jiangsu Medical Science and Technology Award: Research on the mechanism and application of microRNA and important signaling molecules in tumor resistance

The First Prize of Jiangsu Medical Science and Technology: Research on the treatment and prognosis of non-small cell lung cancer guided by molecular markers

Application of Cripto Gene Test in the Diagnosis and Prognosis Evaluation of Colorectal Cancer, Second Prize of Jiangsu Medical Science and Technology

First Prize of New Technology Introduction from Jiangsu Health Department: Clinical study of tamoxifen combined with rapamycin in the treatment of liver cancer

The first prize of the Jiangsu Department of Health New Technology Introduction Award: The clinical value of quality of life assessment combined with immune function testing for targeted therapy in patients with advanced renal cancer

The First Prize of New Technology Introduction from Jiangsu Department of Health: Evaluation of IGF1 and microRNA-196a2 gene polymorphisms on the susceptibility and prognosis of lung cancer in Chinese population

Basic research and clinical application of new targets for personalized diagnosis and treatment of non-small cell lung cancer, Second Prize of Nanjing Science and Technology Progress Award

First Prize of New Technology Introduction Award of Jiangsu Department of Health: Application of miRNA in the clinical diagnosis and treatment of malignant tumors

China Anti-Cancer Association Science and Technology Award Biological target-guided personalized diagnosis and treatment of non-small cell lung cancer


Publish articles and undertake topics:

In recent years, he has published more than 120 SCI articles and four monographs. Undertake 3 national natural science fund projects, national health ministry projects, national "863" projects, major research projects of the Provincial Department of Health and major research projects of the Provincial Science and Technology Commission and the Provincial Education Commission. It has undertaken 8 international multi-center clinical new drug clinical phase II-III studies, 15 domestic multi-center clinical new drug phase II-III studies, and undertook multiple clinical phase IV studies.


Main direction:

Since 1994, he has been engaged in basic and clinical research in clinical oncology, focusing on the diagnosis and treatment of lung cancer and digestive system tumors. In recent years, he has been mainly engaged in the research of new targets for personalized diagnosis and treatment of non-small cell lung cancer, early screening of gastric cancer and genetic strategies for personalized treatment, and molecular immunotherapy of malignant tumors.


Xia Jianchuanprofessor
Director of Biotherapy Center, Director of Somatic

Professor Xia Jianchuan, current director of the Biotherapy Center, doctor of medicine, doctoral supervisor, chairman of the Chinese Society of Medical Bioimmunology, chairman of the Cell Therapy Quality Control and Research Professional Committee of the Chinese Medical Quality Management Association, chairman of the Guangdong Society of Cell Biology, Chairman of the Biotherapy Professional Committee of Guangdong Anti-Cancer Association, Chairman of the Guangdong Immunological and Biological Therapy Professional Committee, Executive Director of China Medical Biotechnology Association, Standing Member of China Biotherapeutic Clinical Application Professional Committee, National Food and Drug Administration New Drug Review Expert , The leader of the immunology and genetic research group of the National Key Laboratory of Oncology in South China. Member of the editorial board of American "Cancer Letter" magazine, executive editor of "Cancer" magazine, expert reviewer for key projects of the National Natural Science Foundation of China and Guangdong Provincial Natural Science Foundation.

Professor Xia Jianchuan graduated from Harbin Medical University in 1998 with a doctor of medicine; from 1998 to 2000, he was engaged in postdoctoral research in the Affiliated Tumor Hospital of Sun Yat-sen Medical University; from 2000 to 2003, he was engaged in tumor immunotherapy at Harvard University Dana-Farber Cancer Institute And tumor vaccine research. During this period, it was confirmed for the first time that the DC/tumor fusion cell vaccine can induce spontaneous breast cancer transgenic mice to produce an anti-tumor immune response, laying the foundation for the application of the DC/tumor fusion cell vaccine in the clinical treatment of tumors. The research results were published in the United States Journal of Immunology (J Immunol 2003 Feb 15; 170 (4): 1980-1986; J Immunol, 2004, 172: 7848-7858; Immunology. 2003 Jun; 109(2): 300-7), June 2003 Returned to China in September, using the advanced somatic cell immunotherapy technology learned abroad to actively carry out basic and clinical application research on tumor somatic immunotherapy, and established the first domestic somatic cell preparation technology operating specifications, somatic cell clinical application safety testing standards and The clinical application standard of somatic immunotherapy has taken an important step on the road to standardization of somatic immunotherapy, and has made important contributions to the safe and effective application of somatic immunotherapy for tumors in the clinical treatment process.

In recent years, he has presided over and participated in a number of major national, provincial and ministerial clinical application research projects, actively carried out basic and clinical application research on tumor etiology and tumor somatic immunotherapy, and published SCI in the field of tumor etiology and tumor somatic immunotherapy More than 50 research papers have been collected. Editor-in-chief of the first domestic textbook "Basic and Clinical Application of Tumor Biotherapy" (published by China Science and Technology Press in August 2011); as an associate editor, he wrote the monograph "Principles of Individualized Medicine" (by People's Medical Publishing House, 2013) Published monthly); participated in the compilation of the undergraduate textbook "Clinical Oncology" for medical colleges and universities and the postgraduate textbook "Clinical Oncology" for medical colleges and universities. Obtained two national invention patents (a technology for separation and purification of human tumor cells. National invention patent number: ZL 03146933.7; OK-432 combined with IFN-γ stimulates the maturation of type I polarized dendritic cells and enhances the anti-tumor immune response. National invention Patent number: 20131004940.6). He has won the second prize of the Provincial Government's Science and Technology Progress Award, and in 2008, the first Guangzhou New Overseas Chinese Students Returned to the Country for Entrepreneurship Contribution Award, and enjoyed special government allowances.



Awards:
      (1) The second prize of Provincial Science and Technology Progress Award;

(2) The first prize of Science and Technology Progress Award of Provincial Education Commission;

(3) In 2008, the first Guangzhou New Overseas Chinese Students Returned to China and Contributed to Entrepreneurship



focus on:

Editor-in-chief "Basic and Clinical Application of Tumor Biotherapy", Beijing, Science Press, 2011;

Associate editor of the monograph "Principles of Individualized Medicine" (published by People's Medical Publishing House in January 2013);

Editor-in-chief "Tumor Biotherapy", Jiangsu Phoenix Science and Technology Press, October 2014;



Obtained a patent:
      (1) Method for separation and purification of human tumor cells Patent number: ZL 03146933.7

(2) Composition and method for stimulating the maturation of dendritic cells Patent No.: ZL 20131004940.6


Wu Peihongprofessor
Director of Medical Imaging and Minimally Invasive

Wu Peihong, graduated from the Department of Medicine, Zhongshan Medical University in 1982. He is currently the director of the Imaging and Minimally Invasive Intervention Center of Sun Yat-sen University Affiliated Tumor Hospital, second-level professor, first-level chief physician, doctoral supervisor and postdoctoral supervisor. Rochester University (Rochester) School of Medicine, Canada University of Toronto School of Medicine Clinical Visiting Professor, Sun Yat-sen University Famous Doctor, Top 10 Minimally Invasive Intervention Therapy in China's Top 100 Famous Doctors.



Part-time professional society:

Executive Director of China Anti-Cancer Association (2007-present)

Executive Director of the Asian Society of Ablation (2014-present)

Chairman of the Society of Minimally Invasive Tumor Therapy under the guidance of Asia Pacific Imaging (2014-present)

Honorary Chairman of the Professional Committee of Minimally Invasive Tumor Therapy of China Anti-Cancer Association (2006-present)

Group Leader of Tumor Ablation Therapy Group under the Image-guided Tumor Minimally Invasive Therapy Committee of China Anti-Cancer Association (2008-present)

Chairman of the Committee of Expert Committee on Minimally Invasive Tumor Therapy under the guidance of imaging guidance of the Chinese Anti-Cancer Association Minimally Invasive Tumor Therapy Committee (2013-present)

Chairman of the Committee of Expert Committee on Minimally Invasive and Comprehensive Treatment of Liver Cancer under the Image-guided Committee of the Chinese Anti-Cancer Association

Honorary Chairman of Particle Therapy Group of China Anti-Cancer Association Minimally Invasive Tumor Therapy Professional Committee (2007-present)

Deputy Chairman of the Interventional Physician Branch of Guangdong Medical Association (2011-present)

Deputy Chairman of Guangdong Medical Association Biological Cell Therapy Association (2012-present)

Vice Chairman of Guangdong Cell Therapy Association (2009-present)

Honorary Chairman of the Professional Committee of Tumor Imaging and Interventional Diagnosis and Treatment of Guangdong Anti-Cancer Association (2011-present)

Chairman of the Professional Committee of Minimally Invasive Tumor Therapy of Guangzhou Anti-Cancer Association (2002-present)

Member of the Standing Committee of the Interventional Oncology Committee of the Chinese Anti-Cancer Association (2001-present)

Member of the Standing Committee of the Guangdong Society of Radiology (1994-present)

Professional magazine editor (reviewer):

Editorial Board Member of "Chinese Medical Journal" (2009-present)

Editorial Board Member of "Chinese Journal of Oncology" (2009-present)

Standing Editor of "Journal of Interventional Radiology" (2003-present)

Standing editorial board member of "Cancer" magazine. (2003-present)

Part-time job at Sun Yat-sen University and Cancer Hospital:

Member of "Academic Committee" (2010-present)

Director of "Image and Diagnostic System Academic Committee" (2010-present)

Member of "Medical Quality Management Committee" (2010-present)

Deputy Director of the Radiological Protection Committee (2010-present)

Member of Guangdong Province and Guangzhou Municipal Health Committee

Member of "Medical Consumables Management Committee" (2010-present)



Overseas study experience:

From 1999 to 2000, he was a visiting scholar at MD.Anderson Cancer Center and Iowa University in the United States to study and exchange tumor imaging diagnosis and minimally invasive interventional therapy.



Clinical medical experience:

It has a solid foundation in medical clinical oncology and imaging, minimally invasive interventional diagnosis and treatment of tumors. Proficiency in the comprehensive application of multiple minimally invasive interventional techniques for tumor treatment. He has more than 30 years of experience in tumor diagnosis and treatment, and various minimally invasive interventional procedures have reached more than 15,000 people. In particular, he has rich experience in liver cancer, lung cancer, breast cancer, cervical cancer, uterine fibroids, abdominal and pelvic tumor intervention, ablation treatment, and seed implantation. Established the concept of radical minimally invasive interventional tumor treatment and minimally invasive interventional tumor lymph node dissection, and applied it to the field of comprehensive tumor treatment; extended the concept of radical tumor treatment to the local inactivation of the tumor, the level and area of the organ where the tumor is located The inactivation of cancer cells at the systemic level. Create and promote a new model of tumor treatment, namely, image-guided minimally invasive or non-invasive treatment combined with biological, molecular targeted therapy, and Chinese medicine treatment of individualized, humanized, rational, and constructive tumor treatment models, which are effective in treating Under the premise of tumor, the physiological function and immune function of the human body are protected to the greatest extent. Established and promoted the transformation of the basic model of interventional therapy for liver cancer, namely TACE sequential combined ablation therapy and biological therapy, which significantly improved the curative effect of liver cancer, reached the world's leading level, reduced liver damage, and improved the quality of life of patients. He is one of the initiators of non-invasive, minimally invasive and comprehensive treatment of breast cancer, and actively promotes the individualized, humanized, and rational constructive treatment of breast cancer. Carry out minimally invasive interventional treatment of a variety of tumors, such as tumor embolization chemotherapy, hemangioma embolization; arterial catheter kit system placement to treat head and neck, chest and abdomen, pelvic cavity, limb tumors; minimally invasive interventional treatment of uterine fibroids; stents Installation treatment of intravenous, arterial and luminal obstruction and stenosis; bone cement vertebroplasty to treat bone metastases; guided biopsy, etc. It is the first in China to carry out intervention-oriented biological gene therapy, arterial chronotherapy, and the combination of tumor anti-vascular therapy (embolization chemotherapy) and anti-neovascular therapy to further improve the efficacy. He has been invited to give lectures at important academic conferences at home and abroad. Co-chairman of WCIO (World Conference on Interventional Oncology); chaired the conference to hold ten National Conferences on Minimally Invasive Tumor Therapy, six National Conferences on Tumor Ablation Therapy, and the first Asia-Pacific Conference on Minimally Invasive Tumor Therapy under imaging guidance



Scientific research experience:

Long-term development of basic and clinical research on minimally invasive interventional therapy for tumors, published more than 200 papers, including more than 40 SCI articles; responsible for the National Natural Science Foundation of China, the National 863 project (the second host and sub-head of the project), There are more than 10 projects in the Ninth Five-Year Plan, the Ministry of Health, the Provincial Natural Science Foundation, the Provincial Science and Technology Commission, the Provincial Health Department, and the 211 Project. Editor-in-chief of 7 monographs, ① "Minimally Invasive Treatment of Liver Cancer and Multidisciplinary Comprehensive Therapy", ② "Tumor Interventional Diagnosis and Treatment", ③ "Tumor Ablation Therapy", ④ "Spiral CT Diagnosis", ⑤ "MRI. Must Read for Clinicians ", ⑥ Ministry of Health medical audio-visual textbook "Nasopharyngeal Carcinoma Imaging Diagnosis"; ⑦ Irreversible electroporation ablation technology application principle and practice. The chief reviewer of the monograph "CT Interventional Therapy"; the deputy editor-in-chief of "Basic and Clinical Application of Tumor Biotherapy"; the editorial board of more than 10 monographs including "Clinical Oncology" and "Oncology". Among them, "Tumor Interventional Diagnosis and Treatment" published by Science Press won the National Science and Technology Academic Publication Fund.



Teaching experience:

Served as the director of the medical imaging teaching and research section of Sun Yat-sen University Cancer Hospital, presided over the training and teaching tasks of undergraduates, postgraduates, imaging professional classes, and advanced students in and outside the province. In 1995 and 2003, he was hired as a postgraduate of imaging medicine and oncology in the Affiliated Tumor Hospital of Sun Yat-sen University. Supervisor, doctoral tutor, post-doctoral tutor; hosting the national continuing medical education class "Minimally Invasive Tumor Treatment and Tumor Imaging" for ten consecutive years.